The PGX-CYP2D6 StripAssay® detects the allelic variants
CYP2D6*4 (1934G>A) and CYP2D6*6 (1795delT)
CYP2D6, a member of the cytochrome P450 superfamily, is one of the most important liver enzymes involved in the metabolism of xenobiotics in the body. Numerous drugs prescribed for the treatment of breast cancer (tamoxifen), cardiac diseases (antiarrhythmics, beta-receptor blockers), psychiatric disorders (antipsychotics, antidepressants) or pain (opiates) are substrates for CYP2D6. Patients with defective enzyme variants are at risk of developing severe adverse reactions due to drug accumulation and toxicity. Conversely, when formation of an active metabolite is essential for the action of a drug, these patients can exhibit diminished response to therapy compared to extensive metabolizers.